US FDA complete response letter for BMS's belatacept
This article was originally published in Scrip
Bristol-Myers Squibb has received a US FDA complete response letter for its injectable immunosuppressant belatacept, requesting longer-term clinical data for the product. It has been filed for the prevention of organ rejection and the preservation of a functioning allograft following kidney transplantation in adult patients when used in combination with an interleukin-2 receptor antagonist, a mycophenolic acid and corticosteroids.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.